Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Does lowering lipoprotein(a) have an impact on cardiovascular risk?
Does lowering lipoprotein(a) have an impact on cardiovascular risk?

Consultant cardiologist Chris Ellis looks at what we know and what we don’t know about lipoproteins, cardiovascular risk and optimal management
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Katsiki N, Vrablik M, Banach M, et al. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals (Basel) 2023;16(4):577.
2. O’Riordan M. Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360. TCTMD, 18 November 2024.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111–88.